Site for 5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder

Brief description of study

Site for 5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder


Clinical Study Identifier: s22-00503
ClinicalTrials.gov Identifier: NCT05452772
Principal Investigator: Michael P. Bogenschutz.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.